Avapritinib D3

Avapritinib D3 is a deuterated form of Avapritinib, a small molecule inhibitor of the receptor tyrosine kinase KIT and platelet-derived growth factor receptor alpha (PDGFRA). It is used for the treatment of gastrointestinal stromal tumors (GISTs) that are unresectable, metastatic or have relapsed after surgery. GISTs are rare tumors that develop in the wall of the gastrointestinal tract, and Avapritinib D3 works by blocking the activity of the KIT and PDGFRA proteins, which are involved in the growth and survival of GISTs. Chemically, Avapritinib D3 is a white to off-white crystalline powder with a molecular weight of 535.62 g/mol. It is highly soluble in water and has a melting point of around 200°C. The deuterated form of Avapritinib has been developed to improve the pharmacokinetic properties of the drug, which means that it is absorbed and distributed more efficiently in the body than the non-deuterated form. This can lead to a more effective and longer-lasting therapeutic effect, as well as reduced dosing frequency and side effects. In summary, Avapritinib D3 is a potent and selective inhibitor of KIT and PDGFRA that is used for the treatment of GISTs. Its deuterated form improves its pharmacokinetic properties, which can enhance its efficacy and reduce side effects.